Ensysce Biosciences, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Ensysce Biosciences, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q3 2024.
  • Ensysce Biosciences, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 75.2 %, a 91.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 75.2 -830 -91.7% Sep 30, 2024
Q2 2024 125 +691 Jun 30, 2024
Q1 2024 107 +476 Mar 31, 2024
Q4 2023 221 +722 Dec 31, 2023
Q3 2023 905 +1.36K Sep 30, 2023
Q2 2023 -566 +206 +26.7% Jun 30, 2023
Q1 2023 -369 +3.86K +91.3% Mar 31, 2023
Q4 2022 -501 +6.83K +93.2% Dec 31, 2022
Q3 2022 -454 -4.7K -111% Sep 30, 2022
Q2 2022 -772 -2.2K -154% Jun 30, 2022
Q1 2022 -4.23K -3.42K -426% Mar 31, 2022
Q4 2021 -7.33K -4.37K -147% Dec 31, 2021
Q3 2021 4.25K +3.02K +246% Sep 30, 2021
Q2 2021 1.42K +542 +61.4% Jun 30, 2021
Q1 2021 -803 -1.32K -255% Mar 31, 2021
Q4 2020 -2.96K -3.25K -1138% Dec 31, 2020
Q3 2020 1.23K +965 +366% Sep 30, 2020
Q2 2020 883 +614 +228% Jun 30, 2020
Q1 2020 520 +253 +94.8% Mar 31, 2020
Q4 2019 286 +20.1 +7.57% Dec 31, 2019
Q3 2019 264 +0.2 +0.08% Sep 30, 2019
Q2 2019 269 Jun 30, 2019
Q1 2019 267 Mar 31, 2019
Q4 2018 265 Dec 31, 2018
Q3 2018 264 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.